Pyrrolidine derivatives as DDRs inhibitors

A compound of formula (I)

• wherein
• Y is absent or is —C(O)—;
• R1 is —(C1-C6)alkylene-NRARB or hydrogen;
• R3 is —(C1-C4)alkyl;
• A is selected from the group consisting of A1, A2, A3
• and bicyclic heteroaryl B,
• wherein * indicates the point of attachment to Y and B is substituted by R2;
• wherein
• R2 is H or selected from the group consisting of halogen, cyano, —NRARB, —C(O)NRARB, —C(O)NRC—(C1-C6)alkylene-NRARB, —C(O)NRC—(C1-C6)alkylene-ORA, —NRAC(O)RB, —ORA, —NRC—(C1-C6)alkylene-ORA, —NRC—(C1-C6)alkylene-NRARB, —C(O)NRA-heterocycloalkyl, heterocycloalkyl, —NRA-heteroaryl, —(C1-C6)alkylene-heterocycloalkyl, —(C1-C6)alkylene-ORA, —O—(C1-C6)alkylene-NRARB, —O—(C1-C6)alkylene-ORA, —O—(C1-C6)alkylene-heterocycloalkyl, —(C1-C6) haloalkyl and —(C1-C6)alkyl;
• RA, RB and RC are independently —(C1-C6)alkyl or hydrogen;
• or RA and RB taken together with the nitrogen they are attached to may form a heterocycloalkyl;
• and wherein each heterocycloalkyl or heteroaryl of R2 is substituted by one or more substituents independently selected from the group consisting of hydrogen, halogen, —(C1-C6)alkyl, —(C1-C6) haloalkyl, —(C1-C6)alkylene-ORA, —ORA, —O—(C1-C6)alkylene-NRARB and —O—(C1-C6)alkylene-ORA;
• or a pharmaceutically acceptable salt of said compound.